‘Ozempic face’ and hair loss: what evidence is there for weight-loss drug side-effects?
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GLP-1 medications cause digestive side effects—nausea, vomiting, diarrhoea, constipation—that are documented in clinical trials and listed as "very common" in patient leaflets because the drugs slow stomach emptying.
- Research published last year found people with diabetes using GLP-1 drugs face double the risk of age-related macular degeneration, while Wegovy patient leaflets also mention non-arteritic anterior ischaemic optic neuropathy as a rare possible side-effect.
- The UK Medicines and Healthcare products Regulatory Agency has warned GLP-1 medicines should not be taken during pregnancy or just before trying to conceive, citing insufficient safety data to know whether they can cause harm to the baby.
- "Ozempic face"—sunken eyes, wrinkles, sagging skin—is not in patient information leaflets but is recognized by surgeons as a result of rapid weight loss generally, not specific to any GLP-1 medication's mechanism.
- New research this week linked GLP-1 medications to hair loss in adults with type 2 diabetes; Mounjaro and Wegovy leaflets already list it as a common side-effect, and researchers attribute the association primarily to reversible telogen effluvium.
- "Ozempic foot"—a bony foot appearance and foot pain—is absent from patient leaflets, though podiatrists note rapid weight loss by any means can reduce fat padding in the heels and balls of the feet.
Why it matters: For the millions of patients on GLP-1 medications, this article's evidence-based breakdown gives doctors a practical tool for counseling: documented risks (digestive issues, double the macular degeneration risk for diabetes patients, MHRA's pregnancy warning) versus anecdotal reports not in leaflets ('Ozempic face,' 'Ozempic foot'). The hair-loss finding alone may affect how patients and clinicians weigh initiation and monitoring decisions.
